☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Fresenius Kabi
Fresenius Kabi Reports the US FDA’s Approval for Tyenne (Biosimilar, tocilizumab-aazg) as a Treatment of Immunological and Oncolog...
March 7, 2024
Fresenius Kabi Launches Tyenne, Europe’s First Tocilizumab Biosimilar for Inflammatory Diseases and COVID-19
November 1, 2023
Fresenius Kabi’s Tyenne (biosimilar, tocilizumab) Receives EC’s Approval for Multiple Inflammatory and Immune Mediated Conditions
September 20, 2023
Fresenius Kabi Reports the Commercial Availability of Plerixafor Injection
August 10, 2023
Fresenius Kabi Launches Idacio (biosimilar, adalimumab) in the US for the Treatment of Chronic Autoimmune Diseases
July 4, 2023
Fresenius Kabi Launches Stimufend (biosimilar, pegfilgrastim) for Febrile Neutropenia in the US
February 17, 2023
Load more...
Back to Home